[
  {
    "ts": null,
    "headline": "Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best Dow stocks to invest in. Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support from hospitals that used reprocessed catheters. U.S. District […]",
    "url": "https://finnhub.io/api/news?id=63aeeac3bd32979ff7630fc032e29dabc5f6c34b241c78e86aa13b2fcdb2007e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749674741,
      "headline": "Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit",
      "id": 135201181,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the best Dow stocks to invest in. Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support from hospitals that used reprocessed catheters. U.S. District […]",
      "url": "https://finnhub.io/api/news?id=63aeeac3bd32979ff7630fc032e29dabc5f6c34b241c78e86aa13b2fcdb2007e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
    "summary": "Johnson &amp; Johnson (NYSE:JNJ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 11, 2025 3:20 PM ETCompany ParticipantsTom Cavanaugh -...",
    "url": "https://finnhub.io/api/news?id=3462f66acb258727043fa82209d45d55b610feb0367f0ec775e753c8c104565d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749664462,
      "headline": "Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript",
      "id": 135194569,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson &amp; Johnson (NYSE:JNJ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 11, 2025 3:20 PM ETCompany ParticipantsTom Cavanaugh -...",
      "url": "https://finnhub.io/api/news?id=3462f66acb258727043fa82209d45d55b610feb0367f0ec775e753c8c104565d"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Johnson & Johnson Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03",
    "summary": "Presenter SpeechAsad Haider We're just right about at time, so let's get started. Tail end of day 3 of our conference, saving the best for last. Very welcome to Tom Cavanaugh, group -- Company",
    "url": "https://finnhub.io/api/news?id=d483fe277b47dd74870b3f4ae15fe504cf6e7f17000725bab5f22dbd2e292557",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749664224,
      "headline": "Transcript : Johnson & Johnson Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03",
      "id": 135194537,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Presenter SpeechAsad Haider We're just right about at time, so let's get started. Tail end of day 3 of our conference, saving the best for last. Very welcome to Tom Cavanaugh, group -- Company",
      "url": "https://finnhub.io/api/news?id=d483fe277b47dd74870b3f4ae15fe504cf6e7f17000725bab5f22dbd2e292557"
    }
  },
  {
    "ts": null,
    "headline": "Daniel Pinto Joins Johnson & Johnson (NYSE:JNJ) Board Bringing Extensive Financial Expertise",
    "summary": "Johnson & Johnson (NYSE:JNJ) recently announced the election of Daniel Pinto, a seasoned executive with extensive experience, to its Board of Directors, potentially reinforcing its strategic oversight. Over the past month, the company's stock price saw a modest increase of 1.45%, in line with broader market trends, amid its significant advancements in clinical studies such as DARZALEX FASPRO®, presented at the ASCO Annual Meeting. While not directly impactful on this movement, these...",
    "url": "https://finnhub.io/api/news?id=f9f98f9bc1019ab58e163f1c20b3ff5b230f634d646a2072eec2bfe8011ea03d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749663271,
      "headline": "Daniel Pinto Joins Johnson & Johnson (NYSE:JNJ) Board Bringing Extensive Financial Expertise",
      "id": 135192983,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) recently announced the election of Daniel Pinto, a seasoned executive with extensive experience, to its Board of Directors, potentially reinforcing its strategic oversight. Over the past month, the company's stock price saw a modest increase of 1.45%, in line with broader market trends, amid its significant advancements in clinical studies such as DARZALEX FASPRO®, presented at the ASCO Annual Meeting. While not directly impactful on this movement, these...",
      "url": "https://finnhub.io/api/news?id=f9f98f9bc1019ab58e163f1c20b3ff5b230f634d646a2072eec2bfe8011ea03d"
    }
  },
  {
    "ts": null,
    "headline": "Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel",
    "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci",
    "url": "https://finnhub.io/api/news?id=0fb2c9884a3d968b1b0c30f15e468bdc5f7226238ff1a399f8ca9a402bd38ad7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749651653,
      "headline": "Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel",
      "id": 135184593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci",
      "url": "https://finnhub.io/api/news?id=0fb2c9884a3d968b1b0c30f15e468bdc5f7226238ff1a399f8ca9a402bd38ad7"
    }
  },
  {
    "ts": null,
    "headline": "Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=e24e46eaaf9cbbeffd2194a1866de392b50bfe53e89613e34461067ed80e6e87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749649809,
      "headline": "Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term",
      "id": 135192985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=e24e46eaaf9cbbeffd2194a1866de392b50bfe53e89613e34461067ed80e6e87"
    }
  },
  {
    "ts": null,
    "headline": "JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?",
    "summary": "JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.",
    "url": "https://finnhub.io/api/news?id=34ea8b51637d8d134aa06a97ce8ac2938b88b3e8b30501f3c8339a2201efd26e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749648960,
      "headline": "JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?",
      "id": 135192169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.",
      "url": "https://finnhub.io/api/news?id=34ea8b51637d8d134aa06a97ce8ac2938b88b3e8b30501f3c8339a2201efd26e"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services",
    "summary": "JNJ, TMUS, BA, and FRAF show strong momentum as earnings growth, market share, and strategic moves fuel investor confidence.",
    "url": "https://finnhub.io/api/news?id=5afed0604ab80e94783c33adb78d1bfff4b4df07ee5db8b8cfc085f951cf38bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749648840,
      "headline": "The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services",
      "id": 135192549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ, TMUS, BA, and FRAF show strong momentum as earnings growth, market share, and strategic moves fuel investor confidence.",
      "url": "https://finnhub.io/api/news?id=5afed0604ab80e94783c33adb78d1bfff4b4df07ee5db8b8cfc085f951cf38bf"
    }
  },
  {
    "ts": null,
    "headline": "New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 3b APEX study showing that TREMFYA® (guselkumab) significantly reduced both signs and symptoms of active psoriatic arthritis (PsA) and inhibited progression of joint structural damage at 24 weeks compared to placebo.1 These data from a late-breaking abstract are among the 30 oral and poster presentations Johnson & Johnson is highlighting at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress.",
    "url": "https://finnhub.io/api/news?id=1fe3e4929f533d57a0b8d682ef058a2ce1502cb95b94821547a6ce63058697c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749643500,
      "headline": "New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis",
      "id": 135180009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 3b APEX study showing that TREMFYA® (guselkumab) significantly reduced both signs and symptoms of active psoriatic arthritis (PsA) and inhibited progression of joint structural damage at 24 weeks compared to placebo.1 These data from a late-breaking abstract are among the 30 oral and poster presentations Johnson & Johnson is highlighting at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress.",
      "url": "https://finnhub.io/api/news?id=1fe3e4929f533d57a0b8d682ef058a2ce1502cb95b94821547a6ce63058697c2"
    }
  },
  {
    "ts": null,
    "headline": "American Century Value Fund Q1 2025 Commentary",
    "summary": "The portfolio seeks to invest in companies where we believe the valuation does not reflect the quality and normal earnings power of the company. Read more here.",
    "url": "https://finnhub.io/api/news?id=0fe4438b555e5c7bf8ad4dc8618e634becc4a5c4765dec012e3fcb26b615cefe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749640500,
      "headline": "American Century Value Fund Q1 2025 Commentary",
      "id": 135187267,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201143780/image_2201143780.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The portfolio seeks to invest in companies where we believe the valuation does not reflect the quality and normal earnings power of the company. Read more here.",
      "url": "https://finnhub.io/api/news?id=0fe4438b555e5c7bf8ad4dc8618e634becc4a5c4765dec012e3fcb26b615cefe"
    }
  },
  {
    "ts": null,
    "headline": "Why defensive stocks could be your best bet in a wild market",
    "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. Think defensive stocks are boring? Dryden Pence, Chief Investment Officer at Pence Capital Management, says you're missing the point. On this episode of Trader Talk, host Kenny Polcari sits down with Pence, a military intelligence veteran turned investment expert, to uncover why defensive sectors like consumer staples, utilities, and healthcare can be your strongest allies in volatile markets. Pence explains how understanding investor psychology, economic fundamentals, and consumer necessities can help investors stay steady amid chaos. If market volatility makes you anxious, this episode might just be the reality check you need. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
    "url": "https://finnhub.io/api/news?id=0e20f3dc789420e8ef094da1986de7d120362b2b075ec3746dfb6c3b4a2bc604",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749639652,
      "headline": "Why defensive stocks could be your best bet in a wild market",
      "id": 135180005,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. Think defensive stocks are boring? Dryden Pence, Chief Investment Officer at Pence Capital Management, says you're missing the point. On this episode of Trader Talk, host Kenny Polcari sits down with Pence, a military intelligence veteran turned investment expert, to uncover why defensive sectors like consumer staples, utilities, and healthcare can be your strongest allies in volatile markets. Pence explains how understanding investor psychology, economic fundamentals, and consumer necessities can help investors stay steady amid chaos. If market volatility makes you anxious, this episode might just be the reality check you need. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
      "url": "https://finnhub.io/api/news?id=0e20f3dc789420e8ef094da1986de7d120362b2b075ec3746dfb6c3b4a2bc604"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech introduces surgical stapler for tissue complexity",
    "summary": "The new stapling technology is set for future exclusive use with the OTTAVA robotic surgical system.",
    "url": "https://finnhub.io/api/news?id=e2f12cdf723007bf6d2d0d97fb8479c4a0fdb7344a9635506c26d3e55587a1ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749634519,
      "headline": "Johnson & Johnson MedTech introduces surgical stapler for tissue complexity",
      "id": 135180016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The new stapling technology is set for future exclusive use with the OTTAVA robotic surgical system.",
      "url": "https://finnhub.io/api/news?id=e2f12cdf723007bf6d2d0d97fb8479c4a0fdb7344a9635506c26d3e55587a1ca"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Says Over 40% Of TREMFYA Patients Achieved ACR50 At Week 24",
    "summary": "Johnson & Johnson: * NEW DATA SHOW TREMFYA® IS THE ONLY IL-23INHIBITORPROVEN TO SIGNIFICANTLY INHIBIT PROGRESSION OF JOINT STRUCTURALDAMAGE IN ACTIVE PSORIATIC ARTHRITIS ...",
    "url": "https://finnhub.io/api/news?id=d294b7754af765a5096e0f79f1e2d545d41d3b219f6e04f689bc0d13fb8b882d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749632353,
      "headline": "Johnson & Johnson Says Over 40% Of TREMFYA Patients Achieved ACR50 At Week 24",
      "id": 135179299,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * NEW DATA SHOW TREMFYA® IS THE ONLY IL-23INHIBITORPROVEN TO SIGNIFICANTLY INHIBIT PROGRESSION OF JOINT STRUCTURALDAMAGE IN ACTIVE PSORIATIC ARTHRITIS ...",
      "url": "https://finnhub.io/api/news?id=d294b7754af765a5096e0f79f1e2d545d41d3b219f6e04f689bc0d13fb8b882d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Launches the ETHICON 4000 Stapler for Elevated Surgical Experience and the Most Secure Staple Line Yet1",
    "summary": "NEW BRUNSWICK - Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, announced the U.S. launch of the ETHICON 4000 Stapler, an advanced surgical stapler designed to...",
    "url": "https://finnhub.io/api/news?id=506268726d4cf81cc28ee09c753ee71eefa99693d333b15da740a9f618d03200",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749631347,
      "headline": "Johnson & Johnson Launches the ETHICON 4000 Stapler for Elevated Surgical Experience and the Most Secure Staple Line Yet1",
      "id": 135179214,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "NEW BRUNSWICK - Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, announced the U.S. launch of the ETHICON 4000 Stapler, an advanced surgical stapler designed to...",
      "url": "https://finnhub.io/api/news?id=506268726d4cf81cc28ee09c753ee71eefa99693d333b15da740a9f618d03200"
    }
  },
  {
    "ts": null,
    "headline": "Dogs Of The Dow Performance Ahead Of The Mag 7 Return",
    "summary": "The Dogs of the Dow investment strategy has generated mixed results over the years but 2025 is proving to be a favorable one for this group of stocks.",
    "url": "https://finnhub.io/api/news?id=1bcb8cebe0a8eb2e29632d680ad3448176979f000f1eea3b5022e15e5a6b68f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749613500,
      "headline": "Dogs Of The Dow Performance Ahead Of The Mag 7 Return",
      "id": 135177326,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503371245/image_1503371245.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Dogs of the Dow investment strategy has generated mixed results over the years but 2025 is proving to be a favorable one for this group of stocks.",
      "url": "https://finnhub.io/api/news?id=1bcb8cebe0a8eb2e29632d680ad3448176979f000f1eea3b5022e15e5a6b68f8"
    }
  }
]